Denali Therapeutics Inc (DNLI NASDAQ) stock market data APIs
$21.0767
0.7(3.3%)
as of February 4, 2026
Try our APIs with
free plan!
Denali Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Prev. Close
21.0767
Open
21.7729
High
22.1659
Low
20.6278
52 wk Range
10.57-23.77
Market Cap
3 323 M
Shares Outstanding
156 M
EPS
-0.74
Beta
1.017
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Denali Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Denali Therapeutics Inc data using free add-ons & libraries
Get Denali Therapeutics Inc Fundamental Data
Denali Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -542 073 984
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.75
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Denali Therapeutics Inc News
New
A Look At Denali Therapeutics (DNLI) Valuation As New ETV Rare Disease Data Presentations Approach
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Denali Therapeutics (DNLI) is back in focus after detaili...
How Denali’s Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors
Denali Therapeutics announced it will present past and ongoing clinical and preclinical data from its Enzyme TransportVehicle (ETV) programs at the 22nd Annual WORLDSymposium in San Diego, highlightin...
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
The fourth-quarter 2025 reporting cycle for the Medical sector is about to pick up pace this week, as most firms are slated to share their earnings results over the next two weeks. The sector mainly ...
PLX: CHMP Delivers Positive Opinion
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT CHMP Positive Opinion for Elfabrio Four-Week Dosing In October 2025, Protalix BioTherapeutics, Inc. (NYSE:PLX) announced that t...
Get Denali Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
